Role of LAP in controlling liver homeostasis
Role of LAP in controlling liver homeostasis
批准号:
BB/W002450/1
负责人:
Naiara Beraza
金额:
$72.24万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Dead cell clearance is a fundamental physiological process essential for tissue homeostasis throughout life, and for efficient responses to multicellular tissue damage; generally termed phagocytosis, it is achieved by professional (immune, myeloid) and non-professional (epithelial, endothelial) phagocytic cells that recognise, internalise and degrade dying cells and extracellular debris.Recently, the novel LC3-dependent phagocytosis (LAP) pathway was described which mediates engulfment of extracellular components and their intracellular processing and degradation. Our research team (co-I: Wileman) has defined the molecular components regulating LAP and how this preserves brain homeostasis and prevents Alzheimer's Disease during old age. Our team also dissected cell-specific LAP functions in other tissues, showing how LAP activation affects sensitivity to influenza virus infection in the lung.To advance our understanding of cell clearance in the liver, we have generated a transgenic mouse in which LAP can be depleted specifically in hepatocytes. This unique experimental tool enables us to dissect the, as yet unknown, role of LAP in hepatocytes and its influence on liver function.This is particularly important since the liver is constantly challenged with antigens and bacterial products circulating from the intestine, as well as an influx of dying lymphocytes from blood circulation. These promote low-grade apoptosis of hepatocytes which are replaced by new hepatocytes after proliferation, a regenerative process tightly regulated by crosstalk with resident macrophages. In response to excessive hepatocyte death after liver injury, this self-regulated interaction can become overwhelmed leading to chronic inflammation and disease progression.Remarkably, despite the well-known capacity of hepatocytes to engulf dead cells, the underpinning mechanisms remain undefined, supporting the urgent need for our research aimed at characterising LAP in hepatocytes and defining its influence on liver function and response to injury.Our pilot results using hepatocyte-specific LAP-deficient mice show that absence of LAP protects the liver from hepatocellular death, inflammation and fibrosis. This indicates that LAP has a specific function in hepatocytes, different from that recently described in myeloid cells infiltrating the liver, and supporting the key role of LAP in hepatocyte modulation of liver response to challenge.Building on our exciting pilot work, here we propose a programme of research that integrates in vitro and in vivo work in murine liver cells and tissue samples, to define the specific role of LAP in hepatocytes for regulation of liver function and immunity.First, we will: define what activates LAP in hepatocytes; characterise the molecular machinery of the LAP pathway; and determine the fate of intracellular cargo in hepatocytes using in vitro techniques that are well-established in our labs.Next, we will determine how hepatocyte-LAP controls liver responses to injury and inflammation in vivo using our unique genetically-modified mice and experimental models, also well-established in our groups. Exploiting the expertise of our team, we will precisely dissect how hepatocyte-LAP activation can influence on other individual liver cell type function during responses to injury using high-throughput 10x single cell sequencing technology.Ultimately, we will apply our expertise in the mechanisms mediating liver regeneration to define the role of LAP in restoration of liver function after challenge and preservation of liver homeostasis.Through this programme of research, we will deliver new fundamental mechanistic insights into the role of hepatocyte-LAP in controlling liver responses to injury and in preventing disease progression. This will enable us to develop future strategies that will reduce hepatocyte injury and thus prevent and treat disease and preserve life-long health.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1126/sciadv.abn3298
发表时间:
2022-10-28
期刊:
Science advances
影响因子:
13.6
作者:
[]
通讯作者:
国内基金
海外基金
登录
查看更多内容
circMRPS12-miR-6889-3p-LAP3轴在胃癌转移中的作用及其机制研究
-
批准号:2025JJ81061
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:唐芬
-
依托单位:
“双钥匙-双锁”GSTs/LAP 激活型荧光探针的构建及肝癌精准诊疗研究
-
批准号:
-
项目类别:青年科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:黄永飞
-
依托单位:
核纤层相关蛋白LAP2α在乳腺癌发生发展中的作用和分子机制探索
-
批准号:82302944
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:张琦
-
依托单位:
针对外泌体LAP-TGF-β1-肺转移前生态位形成“证候”的黄芪-莪术药对药效物质及作用机制研究
-
批准号:82304713
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:余培
-
依托单位:
星形胶质细胞通过C4b/LAP通路调控小胶质细胞碎片清除影响PND发生的机制研究
-
批准号:82301357
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陆燕
-
依托单位:
不全射频消融术后残癌与坏死交界区巨噬细胞LC3相关吞噬作用 (LAP) 介导免疫抑制微环境形成的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:蔡艳
-
依托单位:
巨噬细胞LAP下调IRF8抑制肝癌射频消融术后残癌三级淋巴结构所介导的抗肿瘤免疫研究
-
批准号:82302214
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘晓迪
-
依托单位:
c ircYTHDF2-miR-519b-3p-LAP3 轴在胃癌中的表达意义及调控机制
-
批准号:2022JJ50029
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:伍石华
-
依托单位:
非经典自噬途径LAP通过促进胞葬活性缓解炎症性肠病的实验研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:巫明月
-
依托单位:
基于MDH2succ-LAP通路探讨新型青蒿素衍生物治疗急性胰腺炎的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:潘夕春
-
依托单位: